Ibritumomab tiuxetan (Ibritumomabum tiuxetanum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Radioprophylactic and radiotherapeutic agents

Included in the formulation
АТХ:

V.10.X.X   Various other radiotherapeutic agents

Pharmacodynamics:

Selectively binds to B cells that produce CD20 antigen present on the surface of malignant and normal B lymphocytes, which is released at the stage of cell maturation (pre-B lymphocytes). During the transformation of B-lymphocytes into plasma cells, the CD20 antigen is lost, so the drug does not act on mature, normal lymphocytes, nor does it bind to other leukocytes and other tissues of the human body.

The yttrium-90 isotope is a radiator with a mean free path of β particles of 5 mm, thereby killing the target cells with the B-prolymphocytes surrounding them. The blocking of normal B cells ensures the most effective binding of the drug to the cells of the lymphoma.

The decrease in the number of normal CD20-positive cells has a temporary character - the restoration of normal B cells begins after 6 months, and by the end of 9 months the number of B cells returns to normal limits.

Pharmacokinetics:

After intravenous administration at a dose of 250 mg / m2 body surface and with subsequent intravenous injection at a dose of 25 MBq / kg weight, the half-life period is 28 hours.

Indications:

It is used for the treatment of refractory or recurrent CD20-positive indolent B-cell non-Hodgkin's lymphoma, used for consolidation therapy after remission in previously untreated patients with follicular lymphoma.

ICD-10

II.C81-C96.C82.9   Follicular non-Hodgkin's lymphoma, unspecified

II.C81-C96.C85.1   B-cell lymphoma, unspecified

Contraindications:

Individual intolerance, pregnancy and lactation, children's age.

Carefully:

Condition after transplantation of red bone marrow, thrombocytopenia, condition after radiation therapy, affecting more than 25% of bone marrow.

Pregnancy and lactation:

Recommendations for FDA - Category X. Contraindicated in pregnancy and lactation.

Dosing and Administration:

The course of treatment involves two intravenous injections of the drug:

1 day - in a dose of 250 mg / m2 body surface;

7, 8 or 9 day - 250 mg / m2 body surface for 10 minutes.

The highest daily dose: 1200 MBq / kg.

The highest single dose: 1200 MBq / kg.

Side effects:

Central and peripheral nervous system: asthenia, increased fatigue, dizziness, insomnia.

Respiratory system: cough, runny nose.

The system of hematopoiesis: anemia, neutropenia, pancytopenia, thrombocytopenia, lymphocytopenia.

The cardiovascular system: tachycardia.

Digestive system: anorexia, dyspepsia, diarrhea, constipation.

Musculoskeletal system: arthralgia, neck pain, back pain, myalgia.

Dermatological reactions: itching, petechial rash.

Reproductive system: amenorrhea.

Allergic reactions.

Overdose:

Increased side effects, bleeding due to thrombocythemia.

Treatment is symptomatic.

Interaction:

Not described. It is not recommended to mix in solution with other medications.

Special instructions:

Monitoring the composition of blood, coagulograms.

Treatment should be performed by a specialist with experience in the use of radiopharmaceuticals.

Women and men of reproductive age at the time of taking the drug and in the next 12 months it is recommended to use effective contraception.

Instructions
Up